MK-0457

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-0457, covering 2015-01-26 to 2015-01-26. Get the full timeline:

Most recent: Clinical Trial Update: A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008) [Phase 2]